- The Myeloma Beacon - https://myelomabeacon.org -
Torisel (temsirolimus)
By: Jessica Langholtz; Published: December 3, 2009 @ 3:19 pm | Comments Disabled
| Brand Name: | Torisel |
| Generic Name: | temsirolimus |
| Code Name: | |
| Company: | Pfizer |
| FDA Clinical Phase: | 1/2 |
Description:
Torisel, which is currently approved for treatment of advanced renal cell carcinoma, is being studied for treatment of multiple myeloma in combination with Velcade [1](bortezomib) and dexamethasone [2] (Decadron). Torisel inhibits the mammalian target of rapamycin (mTOR), which is a critical protein for cancer cell growth.
Clinical Trials:
For a list of clinical trials studying Torisel for the treatment of multiple myeloma, see ClinicalTrials.gov [3].
Official Web site for Torisel: http://www.torisel.com/ [4]
Article printed from The Myeloma Beacon: https://myelomabeacon.org
URL to article: https://myelomabeacon.org/resources/2009/12/03/torisel/
URLs in this post:
[1] Velcade : https://myelomabeacon.org/resources/2008/10/15/velcade/
[2] dexamethasone: https://myelomabeacon.org/resources/2008/10/15/dexamethasone/
[3] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=torisel+myeloma
[4] http://www.torisel.com/: http://www.torisel.com/
Click here to print.
Copyright © The Beacon Foundation for Health. All rights reserved.